Table 3 Guideline-adherent treated breast cancer inpatients per therapy sequence and distribution of guideline divergences
N (%) | Institutional-invasive samples | Regional invasive samples | ||||
|---|---|---|---|---|---|---|
|  | 1996–97 | 2003–04 | p-valuea | 1996–97 | 2003–04 | p-valuea |
Surgical strategy incl. irradiation | 99 (28.7) | 210 (52.8) | <0.001 | 72 (30.3) | 138 (51.9) | <0.001 |
Lymph node dissection | 279 (80.9) | 323 (81.2) | n.s. | 188 (79.0) | 209 (78.6) | n.s. |
Planned chemotherapy | 257 (74.5) | 371 (93.2) | <0.001 | 183 (76.9) | 245 (92.1) | <0.001 |
Planned hormontherapy | 242 (70.1) | 336 (84.4) | <0.001 | 162 (68.1) | 223 (83.8) | <0.001 |
Adherence overall | 46 (13.3) | 140 (35.2) | <0.001 | 36 (15.1) | 89 (33.5) | <0.001 |
Divergence overall | 299 (86.7) | 258 (64.8) | 202 (84.9) | 177 (66.5) | ||